Dermatomyositis during adalimumab therapy for rheumatoid arthritis

Journal of Rheumatology

Volumn 37, Issue 7, 2010, Pages 1549-1550

  Brunasso, Alexandramaria Giovanna ^a   Lo Scocco, Giovanni ^b   Massone, Cesare ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b Prato Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; DNA ANTIBODY;

ADULT; AUTOIMMUNITY; CASE REPORT; CLINICAL FEATURE; DERMATOMYOSITIS; DISEASE SEVERITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; LETTER; PAPULE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SKIN BIOPSY;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DERMATOMYOSITIS; FEMALE; HUMANS; MIDDLE AGED;

EID: 77954450420     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.091413     Document Type: Letter

References (11)

1. Callen JP, Wortmann RL. Dermatomyositis. Clin Dermatol 2006;24:363-73.
2. Tincani A, Andreoli L, Bazzani C, Bosiso D, Sozzani S. Inflammatory molecules: a target for treatment of systemic autoimmune diseases. Autoimmun Rev 2007;7:1-7.
3. De Bandt M, Sibilia J, Le Loët X, Prouzeau S, Fautrel B, Marcelli C, et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 2005;7:R545-51.
4. Kiltz U, Fendler C, Braun J. Neuromuscular involvement in rheumatic patients treated with anti-tumor necrosis factor therapy - three examples [letter]. J Rheumatol 2008;35:2074-6.
5. Shimizu T, Tomita Y, Son K, Nishinarita S, Sawada S, Horie T. Elevation of serum soluble tumour necrosis factor receptors in polymyositis and dermatomyositis. Clin Rheumatol 2000;19:352-9.
6. Selva-O'Callaghan A, Martinez-Costa X, Solans-Laque R, Mauri M, Capdevila JA, Vilardell-Tarres M. Refractory adult dermatomyositis with pneumatosis cystoides intestinalis treate with infliximab [letter]. Rheumatology 2004;43:1196-7.
7. Choi KH, Yoo WH. Necrotizing fasciitis in a patient treated with etanercept for dermatomyositis [letter]. Rheumatol Int 2009;29:463-6.
8. Efthimiou P, Schwartzman S, Kagen LJ. Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Ann Rheum Dis 2006;65:1233-6.
9. Via CS, Shustov A, Rus V, Lang T, Nguyen P, Finkelman FD. In vivo neutralization of TNF-alpha promotes humoral autoimmunity by preventing the induction of CTL. J Immunol 2001;167:6821-6.
10. McDevitt H, Munson S, Ettinger R, Wu A. Multiple roles for tumor necrosis factor-alpha and lymphotoxin alpha/beta in immunity and autoimmunity. Arthritis Res 2002;4 Suppl 3:S141-52.
11. Dastmalchi M, Grundtman C, Alexanderson H, Mavragani CP, Einarsdottir H, Helmers SB, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 2008;67:1670-7.